Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study

被引：2
|
作者：
O'Cearbhaill, R. E. [1 ,2 ]
Moore, K. N. [3 ,4 ]
Yeku, O. [5 ]
Liu, J. F. [6 ]
Bouberhan, S. [5 ]
Hamilton, E. P. [7 ]
Hou, J. Y. [8 ]
Van Nieuwenhuysen, E. [9 ]
Papadimitriou, K. [10 ]
Yoo, S-Y. [11 ]
Govindraj, S. [11 ]
Brouwer-Visser, J. [11 ]
Peterman, M. [11 ]
Schmidt, T. [11 ]
Barnes, B. [11 ]
Madia, P. [11 ]
Zhu, M. [11 ]
Uldrick, T. S. [11 ]
Miller, E. A. [11 ]
O'Malley, D. [12 ,13 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[2] Weill Cornell Med Coll, New York, NY USA
[3] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA
[4] Sarah Cannon Res Inst, Oklahoma City, OK USA
[5] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[6] Dana Farber Canc Inst, Med Oncol, Boston, MA USA
[7] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN 5 USA
[8] Columbia Univ, Div Gynecol Oncol, Med Ctr, New York, NY USA
[9] Leuven Canc Inst, Dept Oncol, Leuven, Belgium
[10] Univ Antwerp Hosp, Multidisciplinary Oncol Ctr Antwerp MOCA, Antwerp, Belgium
[11] Regeneron Pharmaceut Inc, Global Dev, Tarrytown, NY USA
[12] Ohio State Univ, Div Gynecol Oncol, Columbus, OH USA
[13] James Canc Ctr, Columbus, OH USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1933
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
754P
引用
收藏
页码：S516 / S517
页数：2
相关论文
共 50 条
  • [41] First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors
    Shimizu, Toshio
    Powderly, John
    Abdul Razak, Albiruni
    Lorusso, Patricia
    Miller, Kathy D.
    Kao, Steven
    Kongpachith, Sarah
    Tribouley, Catherine
    Graham, Michelle
    Stoll, Brian
    Patel, Maulik
    Sahtout, Mohammad
    Blaney, Martha
    Leibman, Rachel
    Golan, Talia
    Tolcher, Anthony
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [42] CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours
    J. Randolph Hecht
    Jean-Marie Michot
    David Bajor
    Amita Patnaik
    Ki Y. Chung
    Judy Wang
    Gerald Falchook
    James M. Cleary
    Richard Kim
    Anuradha Krishnamurthy
    Omkar Marathe
    Hagop Youssoufian
    Catherine Ellis
    Angela Waszak
    Srimoyee Ghosh
    Hailei Zhang
    Kaitlin Yablonski
    Shruti D. Shah
    Ivan Diaz-Padilla
    Susanna Ulahannan
    BJC Reports, 3 (1):
  • [43] A phase I dose-escalation and expansion study of RMX1002, a selective E-type prostanoid receptor 4 antagonist, as monotherapy and in combination with anti-PD-1 antibody in advanced solid tumors
    Liu, Dan
    Gong, Jifang
    Zhang, Jian
    Shu, Yongqian
    Wu, Hao
    Liu, Tianshu
    Xu, Yanhua
    Zhang, Lijia
    Li, Min
    Hu, Xichun
    Shen, Lin
    INVESTIGATIONAL NEW DRUGS, 2025,
  • [44] Phase I dose-escalation study of AGS-PSCA, an anti-PSCA human antibody, in castration-resistant prostate cancer
    Carducci, Michael A.
    Morris, Michael J.
    Eisenberger, Mario A.
    Pili, Roberto
    Denmeade, Samuel R.
    Slovin, Susan F.
    Kelsen, Moshe
    Jacobovits, Aya
    Vincent, Martha
    Scher, Howard I.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3355S - 3355S
  • [45] A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors
    Wei, Xiao-Li
    Ren, Chao
    Wang, Feng-Hua
    Zhang, Yang
    Zhao, Hong-Yun
    Zou, Ben-Yan
    Wang, Zhi-Qiang
    Qiu, Miao-Zhen
    Zhang, Dong-Sheng
    Luo, Hui-Yan
    Wang, Feng
    Yao, Sheng
    Xu, Rui-Hua
    CANCER COMMUNICATIONS, 2020, 40 (08) : 345 - 354
  • [46] Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer
    Pegram, Mark D.
    Borges, Virginia F.
    Ibrahim, Nuhad
    Fuloria, Jyotsna
    Shapiro, Charles
    Perez, Susan
    Wang, Karen
    Stark, Franziska Schaedli
    Luck, Nigel Courtenay
    BREAST CANCER RESEARCH, 2009, 11 (05)
  • [47] Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer
    Mark D Pegram
    Virginia F Borges
    Nuhad Ibrahim
    Jyotsna Fuloria
    Charles Shapiro
    Susan Perez
    Karen Wang
    Franziska Schaedli Stark
    Nigel Courtenay Luck
    Breast Cancer Research, 11
  • [48] A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors
    Naing, Aung
    Gainor, Justin F.
    Gelderblom, Hans
    Forde, Patrick M.
    Butler, Marcus O.
    Lin, Chia-Chi
    Sharma, Sunil
    de Olza, Maria Ochoa
    Varga, Andrea
    Taylor, Matthew
    Schellens, Jan H. M.
    Wu, Hongqian
    Sun, Haiying
    Silva, Antonio P.
    Faris, Jason
    Mataraza, Jennifer
    Cameron, Scott
    Bauer, Todd M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [49] Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study
    Yang, Yunpeng
    Chen, Yu
    Qu, Song
    Liu, Lei
    Chen, Lisha
    Yang, Kunyu
    Huang, Xiaoming
    Li, Jingao
    Wang, Rensheng
    Zhu, Haisheng
    Zhao, Shiwei
    Li, Tao
    Cai, Shengli
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] First-in-human phase 1 dose escalation study of HX009, a novel recombinant humanized anti-PD-1 and CD47 bispecific antibody, in patients with advanced malignancies.
    Roohullah, Aflah
    Ganju, Vinod
    Zhang, Faming
    Zhang, Lei
    Yu, Ting
    Wilkinson, Kate
    Cooper, Adam
    de Souza, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345